IrelandIreland

Elan fights against divorce from Biogen

10.08.2009

Dublin - The honeymoon between Elan and Biogen has been over for a long time, now the marriage of the Irish biotech company and their US partner lies in ruins. The Elan Corporation has filed suit against Biogen Idec Inc. In the Federal Court in New York seeking declaratory and injunctive relief to prevent Biogen Idec from terminating the partnership for Tysabri natalizumab.
In a letter to Elan dated July 28, 2009, Biogen Idec alleged that Elan was in material breach of the Collaboration Agreement by granting Johnson & Johnson an option to finance Elan's purchase of Biogen Idec's 50% interest in Tysabri if Biogen Idec is acquired. Biogen Idec claimed that Elan assigned rights to Tysabri without Biogen Idec's consent, which Elan denies. Biogen's letter triggered a 60-day period ending Sept. 26, after which Biogen Idec may seek to terminate the Tysabri deal. Elan is defiant and wants to close the transaction with Johnson & Johnson as soon as possible.
A year ago the relationship between Eland and Biogen was still functional. The two companies celebrated the second anniversary of Tysabri for the treatment of MS. In September 2008 Elan and Biogen announced the start of a clinical trial for the use of the antibody in the treatment of relapsed or refractory multiple myeloma.
Tysabri is a treatment approved for relapsing forms of MS in the United States and relapsing-remitting MS in the European Union. The recombinant, humanized monoclonal antibody targets the adhesion molecule VLA4 (also known as alpha-4 integrin) that is expressed on the surface of many types of immune cells.

IrelandIreland

20.03.2012

While on a trip to strengthen economic ties between Ireland and California, Ireland's minister for jobs, enterprise and innovation, Richard Bruton, revealed on 15 March that two Irish government organisations have provided...

IrelandIreland

16.03.2012

Dublin – Irish drugmaker Shire plc has agreed to pay US-$100m in upfront for Ferrokin Biosciences Inc., a San Francisco-based specialist for iron chelation therapies. US-$225m could be added if certain milestones are achieved....

IrelandIreland

07.03.2012

Abbott Laboratories is to spend a85m and expand its pharmaceutical manu­facturing facility in Sligo (Ireland), saying that would help the company to ensure its supply of compounds in bio­pharmaceutical areas like virology and...

IrelandIreland

24.01.2012

Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the...

IrelandIreland

13.12.2011

Dublin/Cambridge – The University of Cambridge and Irish drugmaker Elan Pharmaceutical Inc. have joined forces in the battle against Alzheimer’s Disease. Together, the two will create the Cambridge-Elan Centre for Research...

IrelandIreland

07.12.2011

Uppsala/Craigavon - Irish Almac trusts a Swedish platform to develop new cancer drug candidates. As Uppsala-based Beactica announced on Tuesday, its Sprint-technology will be used to identify fragment hits against a number of...

IrelandIreland

05.12.2011

Dublin /New York – Irish Tibotec Pharmaceutical Ltd and Bristol-Myers Squibb (BMS) have entered into a clinical collaboration for the treatment of chronic hepatitis C infections with a combination of BMS’ NS5A replication complex...

IrelandIreland

01.10.2011

Athlone – Biopharma group Alkermes has established its new Irish corporate base following its merger with Elan Drug Tech­nologies. The a712m (US$960m) deal agreed back in May – which saw Alkermes acquire Elan’s Athlone-based drug...

Displaying results 1 to 10 out of 49

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-ireland/article/elan-fights-against-divorce-from-biogen.html

Product of the week

Products

Events

All Events

Current issue

All issues